SQI Diagnostics’ Inc. (TSX-V: SQD) Board of Directors is pleased
to announce the appointment of Andrew Morris, President and CEO of SQI
Diagnostics to the Board of Directors.
Andrew Morris has been with SQI for over nine years and acted as the
Company’s Chief Financial Officer prior to being promoted to President
and CEO in June, 2013. Mr. Morris’s in-depth knowledge of the operations
and his track record in the day-to-day management of SQI Diagnostics’
business functions will be valuable assets to the Board.
Mr. Morris replaces Dr. Peter Lea who has resigned from the Board,
effective immediately. Dr. Lea will continue as an active, non-voting
senior advisor to the Board. Dr. Lea founded SQI Diagnostics in 1999 and
invented and patented the core technology underpinning SQI’s
multiplexing microarray technology and is actively involved day to day
in the role of Founder.
“The Board would like to thank Dr. Lea for his years of service to the
Board and value his ongoing contributions to the leadership of SQI,”
said Claude Ricks, chairman of SQI’s Board of Directors. “We are pleased
to have Mr. Morris as a member of the Board of Directors. His insight,
experience and leadership will assist the Board in guiding the emerging
success of SQI."
About SQI Diagnostics
SQI Diagnostics is a life sciences and diagnostics company serving the
reference lab testing and pharmaceutical development markets. The
Company’s proprietary multiplexed tests and fully automated systems
decrease costs, simplify workflows, increase throughput and decrease
time to results for labs conducting antibody and biomarker testing.
For more information about SQI Diagnostics’ please visit www.sqidiagnostics.com.
FORWARD-LOOKING INFORMATION
This press release
contains certain forward-looking statements, including, without
limitation, statements containing the words “may”, “plan”, “will”,
“estimate”, “continue”, “anticipate”, “intend”, “expect”, “believe”, “in
the process”, “is subject to” and other similar expressions which
constitute “forward-looking information” within the meaning of
applicable securities laws. Forward-looking statements reflect the
Company's current expectation and assumptions, and are subject to a
number of risks and uncertainties that could cause actual results to
differ materially from those anticipated. These forward-looking
statements involve risks and uncertainties including, but not limited
to, the ability of our patents to adequately protect our rights or
permit us to gain or keep any competitive advantage, and our ability to
market and sell our novel multiplexing technologies and detection
platforms. Such statements reflect the current views of the Company with
respect to future events and are subject to certain risks and
uncertainties and other risks detailed from time-to-time in the
Company’s ongoing filings with the securities regulatory authorities,
which filings can be found at www.sedar.com.
Actual results, events, and performance may differ materially. Readers
are cautioned not to place undue reliance on these forward-looking
statements. The Company undertakes no obligation to publicly update or
revise any forward-looking statements either as a result of new
information, future events or otherwise, except as required by
applicable securities laws.
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
Copyright Business Wire 2013